DEF 14A: Absci Corporation Aims to Revolutionize Drug Discovery with AI: 2024 Annual Meeting Focuses on Innovation and Strategic Partnerships

Absci Corporation's 2024 Annual Meeting highlights the company's AI-driven approach to drug discovery, aiming to accelerate therapeutic development and improve patient outcomes.

Summary

• Absci Corporation is leveraging generative AI to transform drug discovery, focusing on creating better biologics faster and reshaping biotech R&D economics.
• The company successfully advanced its internal asset programs, including ABS-101, an anti-TL1A antibody, from conception to candidate phase in 14 months using its AI-driven approach.
• Strategic partnerships with AstraZeneca and Almirall are instrumental in redefining the discovery of new medicines.
• Absci's AI-driven approach compressed the timeline to reach a drug candidate to 14 months, with an anticipated IND submission within 24 months from project inception, at a fraction of traditional costs.
• The company's platform enables a 3-5x multiplier, allowing them to pursue 3-5 drug candidates with the same investment previously required for one.
• The 2024 Annual Meeting of Stockholders will be held virtually on June 12, 2024, with proposals including the election of three Class III directors and ratification of Ernst & Young LLP as the independent registered public accounting firm.
• The board of directors recommends voting FOR the election of Sean McClain, Amrit Nagpal, and Joseph Sirosh, Ph.D. as Class III directors.
• The board of directors recommends voting FOR Proposal No. 2 to ratify the appointment of Ernst & Young LLP as Absci's independent registered public accounting firm for the fiscal year ending December 31, 2024.

Sentiment

Score: 8

Explanation: The document expresses a positive outlook on Absci's future, driven by its innovative AI platform and strategic partnerships. The company's ability to accelerate drug discovery and reduce costs is promising, indicating a strong potential for growth and value creation.

Positives

• Absci's AI-driven approach significantly reduces the time and cost to reach an IND, enabling more innovative drugs to be created with a fixed investment.
• The company's platform allows for enhanced diversification as more pipeline is created per unit investment, increasing ROI.
• Absci's AI technology has the potential to increase the probability of clinical breakthroughs that benefit patients significantly.
• The company's AI models are used to engineer optimal drug properties from the start, enhancing developability probabilities and engineering properties like extended half-life.
• Absci's partnerships with AstraZeneca, Almirall, and PrecisionLife, along with support from academics and the Gates Foundation, highlight its leadership in AI-driven biologics drug discovery.
• Absci was invited to the White House and US Senate's AI Insight Forum on innovation.

Risks

• The company faces risks relating to its financial condition, development and commercialization activities, operations, strategic direction, and intellectual property.
• The company's success depends on its ability to effectively conduct research, drug discovery and development activities with respect to its internal programs and to collaborate with its partners or potential partners with respect to their research, drug discovery and development activities.
• The company is dependent on third parties to support its internal development programs, including for the manufacture and supply of preclinical and clinical supplies of its product candidates or components thereof.

Future Outlook

Absci aims to continue refining and expanding its AI capabilities, remaining committed to creating better biologics faster and transforming the drug discovery process.

Management Comments

• Absci's platform enables a 3-5x multiplier, by which I mean Absci can now pursue 3-5 drug candidates with the same investment previously required for a pharmaceutical company to pursue just one drug candidate, according to Sean McClain, Founder & CEO.
• The enhanced speed at which drug candidates are generated saves overall operational costs and reduces the time patients must wait for new therapeutic alternatives, according to Sean McClain, Founder & CEO.
• With AI, we're not just doing things faster; we're doing them smarter, aligning our efforts with the most promising avenues for therapeutic advancement, according to Sean McClain, Founder & CEO.

Industry Context

Absci's AI-driven approach aims to disrupt the traditional drug discovery process, which is typically time-consuming, capital-intensive, and has a high failure rate. The company's partnerships with established pharmaceutical companies suggest a growing recognition of the potential of AI in drug development.

Comparison to Industry Standards

• Traditional pharma companies invest $50-$100 million per asset over 5+ years to reach IND, while Absci aims to achieve this at a fraction of the cost in a significantly shorter timeframe (14 months to drug candidate).
• Companies like Recursion Pharmaceuticals and Exscientia are also leveraging AI in drug discovery, but Absci's focus on integrating synthetic biology data and wet lab capabilities with generative AI models differentiates its approach.
• Absci's 3-5x multiplier in drug candidate development per unit investment contrasts with the traditional model where a fixed investment typically yields only one drug candidate.

Management Changes

Stakeholder Impact

• Shareholders can expect potential value creation through Absci's innovative AI platform and strategic partnerships.
• Employees will benefit from the company's growth and success in the drug discovery field.
• Patients may gain access to new and more effective medicines developed through Absci's accelerated drug discovery process.
• Suppliers and creditors can expect continued business opportunities with Absci as it expands its operations.

Next Steps

• The company will continue to refine and expand its AI capabilities.
• Absci will continue to advance its internal pipeline of drug asset programs.
• The company will continue to establish collaborations with strategic partners.

Key Dates

Keywords

AI, drug discovery, biologics, generative AI, ABS-101, AstraZeneca, Almirall, partnerships, clinical trials, biotech, pharmaceuticals